Clinical outcome of unselected, previously untreated CLL from study cohorts
| Ref. . | Time to first treatment . | OS . | ||
|---|---|---|---|---|
| TP53mut | TP53wt | TP53mut | TP53wt | |
| 37 | 4.8 y (median) | 7.5 y (median) | 60.9% (at 5 y) | 86.8% (at 5 y) |
| 19 | — | — | 4.6 y (median) | 13.9 y (median) |
| 31 | — | — | 50.7% (at 5 y) | 76.5% (at 5 y) |
| 28 | — | — | 54.6% (at 5 y) | 81.8% (at 5 y) |
| 23 | 0.3 y (median) | 5.3 y (median) | 4.6 y (median) | 12.5 y (median) |
| 39 | 1.5 y (median) | 3.5 y (median) | — | — |
| 26 | — | — | 31.9% (at 5 y) | 74.6% (at 5 y) |
| 45 | — | — | 66.2% (at 5 y) | 85.2% (at 5 y) |
| 27 | — | — | 43.5% (at 5 y) | 68.0% (at 5 y) |
| 13 | 1.8 y (median) | Not reached | 2.5 y (median) | Not reached |
| NOTCH1mut | NOTCH1wt | NOTCH1mut | NOTCH1wt | |
| 37 | 3.5 y (median) | 7.6 y (median) | 75.7% (at 5 y) | 85.1% (at 5 y) |
| 19 | — | — | 3.5 y (median) | 13.9 y (median) |
| 31 | — | — | 56.3% (at 5 y) | 75.2% at 5 y) |
| 28 | 0.2 y (median) | 3.4 y (median) | 63.6% (at 5 y) | 85.5% (at 5 y) |
| 23 | 0.4 y (median) | 5.3 y (median) | 5.5 y (median) | 12.8 y (median) |
| 39 | 3.1 y (median) | 3.1 y (median) | — | — |
| 26 | — | — | 36.3% (at 5 y) | 72.5% (at 5 y) |
| 27 | — | — | 69.9% (at 5 y) | 76.1% (at 5 y) |
| 35 | 3.6 y (median) | 7.5 y (median) | — | — |
| 34 | 1.8 y (median) | 6.0 y (median) | 64% (at 10 y) | 35% (at 10 y) |
| 36 | 0.2 y (median) | 1.2 y (median) | 55% (at 5 y) | 75% (at 5 y) |
| 38 | 45% (at 5 y) | 55% (at 5 y) | 75% (at 5 y) | 95% (at 5 y) |
| 33 | — | — | 10.4 y (median) | Not reached |
| 21 | 0.4 y (median) | 4.9 y (median) | 5.5 y (median) | Not reached |
| 40 | — | — | 38% (at 5 y) | 70% (at 5 y) |
| SF3B1mut | SF3B1wt | SF3B1mut | SF3B1wt | |
| 37 | 3.8 y (median) | 8.0 y (median) | 64.7% (at 5 y) | 86.7% (at 5 y) |
| 31 | — | — | 60.3% (at 5 y) | 73.85 (at 5 y) |
| 28 | 0.2 y (median) | 2.0 y (median) | — | — |
| 23 | 0.1 y (median) | 4.8 y (median) | 5.3 y (median) | 12.2 y (median) |
| 39 | 1.9 y (median) | 3.0 y (median) | — | — |
| 26 | — | — | 53% (at 5 y) | 70.8% (at 5 y) |
| 27 | — | — | 64.9% (at 5 y) | 77.7% (at 5 y) |
| 21 | 0.2 y (median) | 4.7 y (median) | 5.3 y (median) | Not reached |
| 40 | — | — | 46% (at 5 y) | 68% (at 5 y) |
| 29 | 0.8 y (median) | 1.1 y (median) | — | — |
| 32 | — | — | 30.0% (at 10 y) | 77% (at 10 y) |
| 41 | 1.2 y (median) | 5.0 y (median) | — | — |
| IGHVunmut | IGHVmut | IGHVunmut | IGHVmut | |
| 19 | — | — | 11.7 y (median) | Not reached |
| 28 | 0.3 y | 7 y (median) | 74.6% (at 5 y) | 87.3% (at 5 y) |
| 23 | 0.9 y (median) | 9.9 y (median) | 6.7 y (median) | Not reached |
| 26 | — | — | 55.6% (at 5 y) | 76.4% (at 5 y) |
| 27 | — | — | 6.4 y (median) | Not reached |
| 13 | 1.5 y (median) | 9.2 y (median) | 81% (at 5 y) | 88% (at 5 y) |
| 21 | 0.8 y (median) | 9.9 y (median) | 6.4 y (median) | Not reached |
| 29 | 0.3 y (median) | 5.4 y (median) | — | — |
| 10 | — | — | 9.7 y (median) | 24.5 y (median) |
| 11 | — | — | 9.0 y (median) | — |
| 22 | — | — | 7.0 y (median) | Not reached |
| 12 | — | — | 8.0 y (median) | Not reached |
| 25 | — | — | 43% (at 10 y) | 87% (at 10 y) |
| 16 | 5.0 y (median) | Not reached | 3.2 y (median) | — |
| 17 | — | — | 7.0 y (median) | Not reached |
| 20 | — | — | 41% (at 10 y) | 75% (at 10 y) |
| 24 | 2.4 y (median) | 19 y (median) | 9.8 y (median) | 17.9 y (median) |
| 18 | 4.6 y (median) | Not reached | 13.0 y (median) | 23.0 y (median) |
| 15 | 1.1 y (median) | Not reached | 7.0 y (median) | Not reached |
| 14 | 2.8 y (median) | 11.0 y (median) | 9.7 y (median) | Not reached |
| Ref. . | Time to first treatment . | OS . | ||
|---|---|---|---|---|
| TP53mut | TP53wt | TP53mut | TP53wt | |
| 37 | 4.8 y (median) | 7.5 y (median) | 60.9% (at 5 y) | 86.8% (at 5 y) |
| 19 | — | — | 4.6 y (median) | 13.9 y (median) |
| 31 | — | — | 50.7% (at 5 y) | 76.5% (at 5 y) |
| 28 | — | — | 54.6% (at 5 y) | 81.8% (at 5 y) |
| 23 | 0.3 y (median) | 5.3 y (median) | 4.6 y (median) | 12.5 y (median) |
| 39 | 1.5 y (median) | 3.5 y (median) | — | — |
| 26 | — | — | 31.9% (at 5 y) | 74.6% (at 5 y) |
| 45 | — | — | 66.2% (at 5 y) | 85.2% (at 5 y) |
| 27 | — | — | 43.5% (at 5 y) | 68.0% (at 5 y) |
| 13 | 1.8 y (median) | Not reached | 2.5 y (median) | Not reached |
| NOTCH1mut | NOTCH1wt | NOTCH1mut | NOTCH1wt | |
| 37 | 3.5 y (median) | 7.6 y (median) | 75.7% (at 5 y) | 85.1% (at 5 y) |
| 19 | — | — | 3.5 y (median) | 13.9 y (median) |
| 31 | — | — | 56.3% (at 5 y) | 75.2% at 5 y) |
| 28 | 0.2 y (median) | 3.4 y (median) | 63.6% (at 5 y) | 85.5% (at 5 y) |
| 23 | 0.4 y (median) | 5.3 y (median) | 5.5 y (median) | 12.8 y (median) |
| 39 | 3.1 y (median) | 3.1 y (median) | — | — |
| 26 | — | — | 36.3% (at 5 y) | 72.5% (at 5 y) |
| 27 | — | — | 69.9% (at 5 y) | 76.1% (at 5 y) |
| 35 | 3.6 y (median) | 7.5 y (median) | — | — |
| 34 | 1.8 y (median) | 6.0 y (median) | 64% (at 10 y) | 35% (at 10 y) |
| 36 | 0.2 y (median) | 1.2 y (median) | 55% (at 5 y) | 75% (at 5 y) |
| 38 | 45% (at 5 y) | 55% (at 5 y) | 75% (at 5 y) | 95% (at 5 y) |
| 33 | — | — | 10.4 y (median) | Not reached |
| 21 | 0.4 y (median) | 4.9 y (median) | 5.5 y (median) | Not reached |
| 40 | — | — | 38% (at 5 y) | 70% (at 5 y) |
| SF3B1mut | SF3B1wt | SF3B1mut | SF3B1wt | |
| 37 | 3.8 y (median) | 8.0 y (median) | 64.7% (at 5 y) | 86.7% (at 5 y) |
| 31 | — | — | 60.3% (at 5 y) | 73.85 (at 5 y) |
| 28 | 0.2 y (median) | 2.0 y (median) | — | — |
| 23 | 0.1 y (median) | 4.8 y (median) | 5.3 y (median) | 12.2 y (median) |
| 39 | 1.9 y (median) | 3.0 y (median) | — | — |
| 26 | — | — | 53% (at 5 y) | 70.8% (at 5 y) |
| 27 | — | — | 64.9% (at 5 y) | 77.7% (at 5 y) |
| 21 | 0.2 y (median) | 4.7 y (median) | 5.3 y (median) | Not reached |
| 40 | — | — | 46% (at 5 y) | 68% (at 5 y) |
| 29 | 0.8 y (median) | 1.1 y (median) | — | — |
| 32 | — | — | 30.0% (at 10 y) | 77% (at 10 y) |
| 41 | 1.2 y (median) | 5.0 y (median) | — | — |
| IGHVunmut | IGHVmut | IGHVunmut | IGHVmut | |
| 19 | — | — | 11.7 y (median) | Not reached |
| 28 | 0.3 y | 7 y (median) | 74.6% (at 5 y) | 87.3% (at 5 y) |
| 23 | 0.9 y (median) | 9.9 y (median) | 6.7 y (median) | Not reached |
| 26 | — | — | 55.6% (at 5 y) | 76.4% (at 5 y) |
| 27 | — | — | 6.4 y (median) | Not reached |
| 13 | 1.5 y (median) | 9.2 y (median) | 81% (at 5 y) | 88% (at 5 y) |
| 21 | 0.8 y (median) | 9.9 y (median) | 6.4 y (median) | Not reached |
| 29 | 0.3 y (median) | 5.4 y (median) | — | — |
| 10 | — | — | 9.7 y (median) | 24.5 y (median) |
| 11 | — | — | 9.0 y (median) | — |
| 22 | — | — | 7.0 y (median) | Not reached |
| 12 | — | — | 8.0 y (median) | Not reached |
| 25 | — | — | 43% (at 10 y) | 87% (at 10 y) |
| 16 | 5.0 y (median) | Not reached | 3.2 y (median) | — |
| 17 | — | — | 7.0 y (median) | Not reached |
| 20 | — | — | 41% (at 10 y) | 75% (at 10 y) |
| 24 | 2.4 y (median) | 19 y (median) | 9.8 y (median) | 17.9 y (median) |
| 18 | 4.6 y (median) | Not reached | 13.0 y (median) | 23.0 y (median) |
| 15 | 1.1 y (median) | Not reached | 7.0 y (median) | Not reached |
| 14 | 2.8 y (median) | 11.0 y (median) | 9.7 y (median) | Not reached |
Clinical outcome of unselected, previously untreated CLL from study cohorts including >200 patients stratified according to the TP53, NOTCH1, SF3B1, and IGHV mutation status. —, not available; Ref., reference.